Rep. Jefferson Shreve Purchases Shares of Zoetis Inc. (NYSE:ZTS)

Representative Jefferson Shreve (R-Indiana) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Zoetis stock on March 5th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 3/31/2025.
• Purchased $50,001 – $100,000 in shares of Block (NYSE:XYZ) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of DuPont de Nemours (NYSE:DD) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of United Community Banks (NASDAQ:UCB) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of IDEX (NYSE:IEX) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of HNI (NYSE:HNI) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of ServiceNow (NYSE:NOW) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Coinbase Global (NASDAQ:COIN) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Constellation Energy (NASDAQ:CEG) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of Simon Property Group (NYSE:SPG) on 3/31/2025.

Zoetis Stock Performance

Shares of ZTS traded down $2.08 during trading hours on Wednesday, reaching $147.14. 996,694 shares of the company’s stock traded hands, compared to its average volume of 2,561,770. The business’s fifty day simple moving average is $161.51 and its two-hundred day simple moving average is $170.76. The firm has a market capitalization of $65.65 billion, a price-to-earnings ratio of 26.90, a P/E/G ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.36%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZTS. Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Stifel Nicolaus lowered their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Barclays raised their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $214.40.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zoetis

A number of institutional investors and hedge funds have recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. boosted its position in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp bought a new position in shares of Zoetis in the fourth quarter valued at $44,000. Finally, Asset Planning Inc bought a new stake in shares of Zoetis in the 4th quarter valued at about $58,000. Institutional investors own 92.80% of the company’s stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.